Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-World Effectiveness of Arexvy (RSVPreF3) in Adults ≥60 Years (BronquiVal)
2026-526804-59-00Phase 4Authorised
- Sponsor
- Foundation for the Incentive of Research
- Start
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of GSK3003899A in respiratory syncytial virus disease (RSV), pulmonary infection, chronic obstructive pulmonary disease exacerbation and 1 more (2 arms), sponsored by Foundation for the Incentive of Research. Primary endpoint: First hospitalisation for RSV-related respiratory disease. Planned start Sep 2026; status: authorised.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)pulmonary infectionchronic obstructive pulmonary disease exacerbationasthma exacerbation
Beyond the preview
Go deeper on 2026-526804-59-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526804-59-00.